About AllCaN Oesophageal
About AllCaN Oesophageal
What is AllCaN Oesophageal?
The Breakthrough All-Ireland Cancer Network (AllCaN) Oesophageal programme represents a new, focused effort to implement advances in Oesophageal Cancer research as rapidly as possible through the creation of a collaborative, translational cancer research network.
The most talented and promising researchers across Irish institutions will be assembled into an All-Ireland Research Network forming an optimal configuration of expertise needed to solve key problems in Oesophageal Cancer research and positively impact patients in the near future.

This network will span multiple disciplines and utilise their expertise to address research questions in a coordinated way. The network will have mechanisms for sharing of resources and platforms (knowledge, talent, tools, technologies, etc.) across the team including existing platforms and resources as well as those to be developed, incorporating new methods and technologies into the research groups, and training and networking across the network.
Mechanisms to foster collaborations within and among the network will be employed, an approach that promotes the sharing of information and a goal-oriented focus on measurable milestones of progress. AllCaN Oesophageal will establish the first national network bringing together scientific, clinical and industry teams with decades of collective experience in Barrett’s Oesophagus (BO) and Oesophageal Cancer (OC).
AllCaN Oesophageal will combine interdisciplinary approaches and world-renowned resources to address major health problems on the island of Ireland in Oesophageal Cancer.
By combining data and resources across Ireland, AllCaN Oesophageal will uniquely identify appropriate prevention strategies, lifestyle interventions and novel diagnostic platforms and therapeutics through enhanced understanding of the BO-OAC progression. Importantly, early detection will lead to better survival outcomes for patients.
AllCaN Oesophageal propose research projects to:
- Monitor the number of patients being diagnosed with Barrett’s oesophagus and oesophageal cancer, and for the first time make North/South comparisons that combine Barrett’s registries in Northern Ireland and the Republic of Ireland (including over 33,000 patients), and cancer registries. AllCaN Oesophageal will examine if there are any inequalities according to where people live, their age and sex, and whether different healthcare systems on the island influence patient outcomes.
- Investigate lifestyle factors and medications in patients with reflux and Barrett’s oesophagus, to determine their importance in progression to oesophageal cancer.
- Work with partners in primary care (GPs) to evaluate potential prevention strategies.
- Conduct exercise and dietary counselling interventions to help improve body composition, without increasing reflux symptoms in patients with Barrett’s oesophagus and examine how these interventions improve outcomes for patients after oesophageal cancer surgery.
- Assess the impact of living with Barrett’s oesophagus or oesophageal cancer on mental health and wellbeing.
- Better understand which Barrett’s oesophagus patients are at low or high risk of developing cancer based on biomarkers measured in their oesophageal tissue.
- Better understand how controlling inflammation can boost responses to treatments.
About AllCaN Oesophageal
Who is leading AllCaN Oesophageal?

AllCaN Oesophageal Team Leader
Professor Jacintha O’Sullivan
Professor in Translational Oncology and Education Director for the Trinity St. James’s Cancer Institute, Department of Surgery, Trinity College Dublin

AllCaN Oesophageal Team Co-Leader
Professor Helen Coleman

AllCaN Oesophageal Team Co-Leader
Professor Juliette Hussey

AllCaN Oesophageal Programme Manager
Dr James Phelan
AllCaN Oesophageal will maximise the training of research leaders through blending skills in:
- Public health/epidemiology/statistics/bioinformatics;
- Exercise and nutrition interventions;
- Diagnostic platform development and;
- Novel therapeutic approaches to boost therapy response across the BO-OAC disease progression model.
Specifically, by monitoring the number of patients with BO and OC across the island of Ireland, AllCaN Oesophageal will examine for the first-time if potential inequalities exist across demographics, healthcare systems and patient outcomes and how lifestyle factors and medications influence reflux symptoms and progression.
Lifestyle interventions will be tailored to reduce symptoms and improve quality of life (including mental health and wellbeing). In collaboration with industry, the biomarker and therapeutic programmes will accelerate translation of relevant diagnostic and prognostic discoveries into clinical practice.
We will provide excellent opportunities for early career trainees within a structured programme, linked with industry partners, mobility research secondments and patient involvement. The outputs of AllCaN Oesophageal will significantly improve the management and outcomes for BO and OC patients.